{"id":"NCT03905330","sponsor":"Mirum Pharmaceuticals, Inc.","briefTitle":"A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)","officialTitle":"MRX-502: Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC) - MARCH-PFIC","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-07-09","primaryCompletion":"2022-09-01","completion":"2022-09-01","firstPosted":"2019-04-05","resultsPosted":"2023-12-11","lastUpdate":"2023-12-11"},"enrollment":93,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Progressive Familial Intrahepatic Cholestasis (PFIC)"],"interventions":[{"type":"DRUG","name":"Maralixibat","otherNames":["Formerly LUM001 and SHP625"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Maralixibat","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether the investigational treatment (maralixibat) is safe and effective in pediatric participants with Progressive Familial Intrahepatic Cholestasis (PFIC).","primaryOutcome":{"measure":"Mean Change in the Average Morning ItchRO(Obs) Severity Score in the Primary Cohort","timeFrame":"MMRM model was used with inputs of the average changes from baseline (BL) to Weeks 1-6, 7-10, 11-14, 15-18, 19-22, 23-26, and other covariates. The average change from BL over Weeks 15-26 is calculated in the model and presented as a single number.","effectByArm":[{"arm":"Primary Cohort Maralixibat","deltaMin":-1.718,"sd":null},{"arm":"Primary Cohort Placebo","deltaMin":-0.628,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"= 0.0063"}]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":31,"countries":["United States","Argentina","Austria","Belgium","Brazil","Canada","Colombia","France","Germany","Hungary","Italy","Lebanon","Mexico","Poland","Singapore","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["38723644"],"seeAlso":["https://ghr.nlm.nih.gov/condition/progressive-familial-intrahepatic-cholestasis","https://clinicaltrials.gov/ct2/info/fdalinks","https://mirumpharma.com/"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":47},"commonTop":["Diarrhoea","Pyrexia","Abdominal pain","Rhinorrhoea","Pruritus"]}}